The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and ...
A Japanese version of the U.S. Esophageal Hypervigilance and Anxiety Scale questionnaire to investigate the psychological ...
The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...
With a sustained 7% annual growth rate, the CDMO sector reflects a fundamental shift in how modern medicines are brought to ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...